Assessment of Immunomodulatory Activities and in vitro Toxicity of New Quinolone 7-ethyl 9-ethyl-6-oxo-6,9-dihydro[1,2,5]selenadiazolo[3,4-h]quinoline-7-carboxylate

Immunological Investigations

Volumn 46, Issue 4, 2017, Pages 341-360

  Jantová, Soňa ^a   Paulovičová, Ema ^b   Paulovičová, Lucia ^b   Topoľská, Dominika ^a,c   Pánik, Miroslav ^a   Milata, Viktor ^a  

^a SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

Author keywords

Anticancer; apoptosis; cytokines; cytotoxicity; HL 60; immunomodulation; proliferation; quinolones

Indexed keywords

7 ETHYL 9 ETHYL 6 OXO 6,9 DIHYDRO[1,2,5]SELENADIAZOLO[3,4 H]QUINOLINE 7 CARBOXYLATE; CARBOXYLIC ACID DERIVATIVE; CYTOTOXIC AGENT; FREE RADICAL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 7-ETHYL 9-ETHYL-6-OXO-6,9-DIHYDRO(1,2,5)SELENADIAZOLO(3,4-H)QUINOLINE-7-CARBOXYLATE; ANTINEOPLASTIC AGENT; ORGANOSELENIUM DERIVATIVE; QUINOLONE DERIVATIVE;

A-549 CELL LINE; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FIBROBLAST; GROWTH INHIBITORY CONCENTRATION; HL-60 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAW 264.7 CELL LINE; TUMOR IMMUNITY; ADENOCARCINOMA; ANIMAL; CELL GROWTH; DRUG EFFECTS; IMMUNOMODULATION; LEUKEMIA; PATHOLOGY; SYNTHESIS;

A549 CELLS; ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL GROWTH PROCESSES; FIBROBLASTS; HL-60 CELLS; HUMANS; IMMUNOMODULATION; LEUKEMIA; MACROPHAGES; MICE; ORGANOSELENIUM COMPOUNDS; QUINOLONES; RAW 264.7 CELLS;

EID: 85015069623     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820139.2017.1280050     Document Type: Article

References (70)

1. Abdel-Aziz M, Park SE, Abuo-Rahma Gel D, et al. 2013. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids:synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity. Eur J Med Chem, 69, 427–438.
2. Azema J, Guidetti B, Dewelle J, Le Calve B, et al. 2009. 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin:synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg Med Chem, 17, 5396–5407.
3. Barbierikova Z, Bella M, Kucerak J, et al. 2011a. Photoinduced superoxide radical anion and singlet oxygen generation in the presence of novel selenadiazoloquinolones (an EPR Study). Photochem Photobiol, 87, 32–44.
4. Barbierikova Z, Bella M, Lietava J, et al. 2011b. Spectroscopic characterization and photoinduced processes of 4-oxoquinoline derivatives. J Photoch Photobio A, 224, 123–134.
5. Barbieriková Z, Bella M, Sekeráková, Ľ, et al. 2013. Spectroscopic characterization, photoinduced processes and cytotoxic properties of substituted N-ethyl selenadiazoloquinolones. J Phys Organic Chem, 26, 565–574.
6. Barrett AJ, Le Blanc K., 2010. Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol 161, 223–232.
7. Bella M, Milata V., 2014. Synthesis of 9-ethyl[1,2,5]selenadiazolo[3,4-h]quinolones by the application of modified Gould-Jacobs reaction to N-ethyl-2,1,3-benzoselenadiazol-4- amine. Arkivoc, 181–198.
8. Blasi F, Tarsia P, Aliberti S, et al. 2006. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm Pharmacol Ther, 19(Suppl 1), 11–19.
9. Cheng YY, Yang JS, Tsai SC, et al. 2012. The newly synthesized 2-(3-hydroxy-5-methoxyphenyl)-6,7-methylenedioxyquinolin-4-one triggers cell apoptosis through induction of oxidative stress and upregulation of the p38 MAPK signaling pathway in HL-60 human leukemia cells. Oncol Rep, 28, 1482–1490.
10. Chou LC, Yang JS, Huang LJ, et al. 2009. The synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells. J Gastroenterol, 44, 1055–1063.
11. Chung DT, Tsai CY, Chen SJ, et al. 2010. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother, 54, 411–417.
12. Costello RT., 1993. Therapeutic use of granulocyte-macrophage colony-stimulating factor (GM-CSF). A review of recent experience. Acta Oncol, 32, 403–408.
13. Crane JK, Mongiardo KM., 2014. Pro-inflammatory effects of uric acid in the gastrointestinal tract. Immunol Invest, (43), 255–266.
14. Dalhoff A., 2005. Immunomodulatory activities of fluoroquinolones. Infection, (33), 55–70.
15. Dalhoff A, Shalit I., 2003. Immunomodulatory effects of quinolones. Lancet Infectious Dis, 3, 359–371.
16. Drygin D, Siddiqui-Jain A, O’Brien S, et al. 2009. Anticancer activity of CX-3543:a direct inhibitor of rRNA biogenesis. Cancer Res, 69, 7653–7661.
17. Du P, Viswanathan UM, Khairan K, et al. 2014. Synthesis of amphiphilic, chalcogen-based redox modulators with in vitro cytotoxic activity against cancer cells, macrophages and microbes. Medchemcomm, 5, 25–31.
18. Eucker J, Zang C, Zhou Y, et al. 2014. TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro. Anticancer Res, 34, 4899–4907.
19. Fallon J, Tighe R, Kradjian G, et al. 2014. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget, 5, 1869–1884.
20. Farzin H, Toroghi R, Haghparast A., 2016. Up-Regulation of pro-inflammatory cytokines and chemokine production in avian influenza H9N2 virus-infected human lung epithelial cell line (A549). Immunol Inves, 45, 116–129.
21. George S, Pili R., 2013. Tasquinimod:a novel angiogenesis inhibitor-development in prostate cancer. Curr Oncol Rep, 15, 65–68.
22. Gruia MI, Negoita V, Vasilescu M, et al. 2015. Biochemical action of new complexes of ruthenium with quinolones as potential antitumor agents. Anticancer Res, 35, 3371–3378.
23. Hamilton-Miller JM., 2001. Immunopharmacology of antibiotics:direct and indirect immunomodulation of defence mechanisms. J Chemother 13, 107–111.
24. Hasinoff BB, Wu X, Nitiss JL, et al. 2012. The anticancer multikinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol, 84, 1617–1626.
25. Hotinski AK, Lewis ID, Ross DM., 2015. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia. Expert Opin Pharmacother, 16, 1395–1402.
26. Huang L, Hsieh M, Teng C, et al. 1998. Synthesis and antiplatelet activity of phenyl quinolones. Bioorg Med Chem, 6, 1657–1662.
27. Huang SM, Yang JS, Tsai SC, et al. 2011. The novel synthesized 2-(3-(methylamino)phenyl)-6-(pyrrolidin-1-yl)quinolin-4-one (Smh-3) compound induces G2/M phase arrest and mitochondrial-dependent apoptotic cell death through inhibition of CDK1 and AKT activity in HL-60 human leukemia cells. Int J Oncol, 38, 1357–1364.
28. Jantová S, Cipak L, Letašiová S., 2007. Berberine induces apoptosis through a mitochondrial/caspase pathway in human promonocytic U937 cells. Toxicol In Vitro, 21, 25–31.
29. Jantová S, Konariková K, Letašiová S, et al. 2011. Photochemical and phototoxic properties of ethyl 1,4-dihydro-8-nitro-4-oxoquinoline-3-carboxylate, a new quinoline derivative. J Photochem Photobiol, B 102, 77–91.
30. Jantová S, Letašiová S, Koňariková K, et al. 2010. Effect of new synthetically prepared quinolone ethyl-1,4-dihydro-8-nitro-4-oxoquinoline-3-carboxylate on human leukemia cell line HL-60 without/with presence of UVA irradiation. Acta Chimica Slovaca, 3, 51–72.
31. Jantová S, Mrvová N, Hudec R, et al. 2016. Pro-apoptotic effect of new quinolone 7-ethyl-9-ethyl-6-oxo-6,9-dihydro[1,2,5]selenadiazolo[3,4-h]quinoline-7-carboxylate on cervical cancer cell line HeLa alone/with UVA irradiation. Toxicol In Vitro, 33, 35–44.
32. Kakadiya R, Wu YC, Dong H, et al. 2011. Novel 2-substituted quinolin-4-yl-benzenesulfonate derivatives:synthesis, antiproliferative activity, and inhibition of cellular tubulin polymerization. ChemMedChem, 6, 1119–1129.
33. Khader SA, Gopal R., 2010. IL-17 in protective immunity to intracellular pathogens. Virulence, 1, 423–427.
34. Khan AA, Slifer TR, Remington JS., 1998. Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob Agents Chemother, 42, 1713–1717.
35. Koziel R, Szczepanowska J, Magalska A, et al. 2010. Ciprofloxacin inhibits proliferation and promotes generation of aneuploidy in Jurkat cells. J Physiol Pharmacol, 61, 233–239.
36. Kullberg BJ, Vantwout JW., 1994. Cytokines in the treatment of fungal-infections. Biotherapy, 7, 195–210.
37. Kuroki M, Miyamoto S, Morisaki T, et al. 2012. Biological response modifiers used in cancer biotherapy. Anticancer Res, 32, 2229–2233.
38. Kuwahara K, Kitazawa T, Kitagaki H, et al. 2005. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci, 38, 47–55.
39. Lai TY, Yang JS, Wu PP, et al. 2010. The quinolone derivative CHM-1 inhibits murine WEHI-3 leukemia in BALB/c mice in vivo. Leuk Lymphoma, 51, 2098–2102.
40. Landskron G, De la Fuente M, Thuwajit P, et al. 2014. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res, 2014, 149185.
41. Leibovitz E., 2006. The use of fluoroquinolones in children. Curr Opin Pediatr 18, 64–70.
42. Letašiová S, Jantová S, Čipák L, Múčková M., 2006. Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett, 239, 254–262.
43. Mantovani A, Pierotti MA., 2008. Cancer and inflammation:a complex relationship. Cancer Lett, 267, 180–181.
44. Meyer E, Schwab F, Gastmeier P, et al. 2007. Antifungal use in intensive care units. J Antimicrob Chemother, 60, 619–624.
45. Mihich E., 2000. On the immunomodulating effects of anti-cancer drugs and their therapeutic exploitation. Jpn J Clin Oncol, 30, 469–471.
46. Mocellin S, Marincola FM, Young HA., 2005. Interleukin-10 and the immune response against cancer:a counterpoint. J Leukoc Biol, 78, 1043–1051.
47. Ono Y, Ohmoto Y, Ono K, et al. 2000. Effect of grepafloxacin on cytokine production in vitro. J Antimicrob Chemother, 46, 91–94.
48. Oriel JD., 1989. Use of quinolones in chlamydial infection. Rev Infect Dis, 11(Suppl 5), S1273–S1276.
49. Repicky A, Jantova S, Cipak L., 2009. Apoptosis induced by 2-acetyl-3-(6-methoxybenzothiazo)-2-yl-amino-acrylonitrile in human leukemia cells involves ROSmitochondrial mediated death signaling and activation of p38 MAPK. Cancer Lett, 277, 55–63.
50. Riesbeck K., 2002. Immunomodulating activity of quinolones:review. J Chemother 14, 3–12.
51. Riesbeck K, Forsgren A., 1994. Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacin. Immunopharmacology, 27, 155–164.
52. Santos Fda C, Abreu P, Castro HC, et al. 2009. Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives. Bioorg Med Chem, 17, 5476–5481.
53. Sayers TJ., 2011. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother, 60, 1173–1180.
54. Scatena CD, Kumer JL, Arbitrario JP, et al. 2010. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol, 66, 881–888.
55. Shaikh PZ., 2011. Cytokines & their physiologic and pharmacologic functions in inflammation:A review. Int J Pharmacy Life Sci, 2, 1247–1263.
56. Shalit I., 1991. Immunological aspects of new quinolones. Eur J Clin Microbiol Infect Dis, 10, 262–266.
57. Sharma PC, Jain A, Jain S., 2009. Fluoroquinolone antibacterials:a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm, 66, 587–604.
58. Sokolova GB, Kunichan AD, Lazareva Ia V., 2009. [Levofloxacin (Tavanic) in complex therapy of tuberculosis]. Antibiot Khimioter, 54, 31–37.
59. Stieglitz E, Ward AF, Gerbing RB, et al. 2015. Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia:a report from the Children’s Oncology Group. Pediatr Blood Cancer, 62, 629–636.
60. Tawfik AF, Shoeb HA, Bishop SJ, et al. 1990. Influence of new quinolones on normal immune capabilities. J Chemother, 2, 300–305.
61. Vickers IE, Smikle MF., 2006. The immunomodulatory effect of antibiotics on the secretion of tumour necrosis factor alpha by peripheral blood mononuclear cells in response to Stenotrophomonas maltophilia stimulation. West Indian Med J, 55, 138–141.
62. Vinayaka AC, Sadashiva MP, Wu X, et al. 2014. Facile synthesis of antimalarial 1,2-disubstituted 4-quinolones from 1,3-bisarylmonothio-1,3-diketones. Org Biomol Chem, 12, 8555–8561.
63. Williams AC, Galley HF, Watt AM, Webster NR., 2005. Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother, 56, 502–506.
64. Winter E, Chiaradia LD, Silva AH, et al. 2014. Involvement of extrinsic and intrinsic apoptotic pathways together with endoplasmic reticulum stress in cell death induced by naphthylchalcones in a leukemic cell line:advantages of multi-target action. Toxicol In Vitro, 28, 769–777.
65. Xia Y, Yang ZY, Xia P, et al. 2001. Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents. J Med Chem, 44, 3932–3936.
66. Xue X, Lai KT, Huang JF, et al. 2006. Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib. J Pharmacol Exp Ther, 317, 53–60.
67. Yanamandra N, Buzzeo RW, Gabriel M, et al. 2011. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J Pharmacol Exp Ther, 337, 636–643.
68. Yang JS, Park CH, Lee C, et al. 2014. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents. Eur J Med Chem, 85, 399–407.
69. You QD, Li ZY, Huang CH, et al. 2009. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. J Med Chem, 52, 5649–5661.
70. Zhang L, Freeman LE, Nakamura J, et al. 2010. Formaldehyde and leukemia:epidemiology, potential mechanisms, and implications for risk assessment. Environ Mol Mutagen, 51, 181–191.